211 related articles for article (PubMed ID: 26511815)
1. A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting.
Baek SK; Kim DY; Kang SY; Sym SJ; Kim YS; Lee JY
Cancer Res Treat; 2016 Apr; 48(2):768-74. PubMed ID: 26511815
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.
Ferrero VT; Oset MM; Masferrer JP; Pardo EH; Sorolla EJ; Largo SC;
Clin Transl Oncol; 2019 Dec; 21(12):1707-1711. PubMed ID: 30949931
[TBL] [Abstract][Full Text] [Related]
3. Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP).
Camps Herrero C; Reina Zoilo JJ; Monge Martín D; Caballero Martínez F; Guillem Porta V; Aranda Aguilar E; Carrato Mena A; Díaz-Rubio García E; García-Foncillas López J; Feijóo Saus M; López López R
Clin Transl Oncol; 2019 Mar; 21(3):380-390. PubMed ID: 30094793
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
5. Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey.
Shin J; Kim DY; Lee J; Choi YS; Hwang IG; Baek SK; Seo MS; Shim JY
J Cancer Educ; 2018 Apr; 33(2):284-292. PubMed ID: 27623849
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm.
Canal-Sotelo J; Trujillano-Cabello J; Larkin P; Arraràs-Torrelles N; González-Rubió R; Rocaspana-Garcia M; Barallat-Gimeno E
BMC Palliat Care; 2018 May; 17(1):81. PubMed ID: 29807537
[TBL] [Abstract][Full Text] [Related]
7. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain.
Mercadante S; Adile C; Masedu F; Valenti M; Aielli F
J Pain Symptom Manage; 2019 May; 57(5):966-970. PubMed ID: 30822530
[TBL] [Abstract][Full Text] [Related]
9. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Husic S; Imamovic S; Matic S; Sukalo A
Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough Cancer Pain: Ten Commandments.
Mercadante S; Cuomo A
Value Health; 2016; 19(5):531-6. PubMed ID: 27565269
[TBL] [Abstract][Full Text] [Related]
13. Knowledge and practice of the management of breakthrough cancer pain among general practitioners providing palliative care in Shanghai, China: a cross-sectional survey.
Yu Y; Zhang P; Chen D; Jiang SF
BMJ Open; 2023 Sep; 13(9):e073670. PubMed ID: 37770268
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough cancer pain: The importance of the right treatment at the right time.
O'Hagan P; Mercadante S
Eur J Pain; 2018 Aug; 22(7):1362-1374. PubMed ID: 29635732
[TBL] [Abstract][Full Text] [Related]
15. Breakthrough cancer pain: review and calls to action to improve its management.
Camps Herrero C; Batista N; Díaz Fernández N; Escobar Álvarez Y; Gonzalo Gómez A; Isla Casado D; Salud A; Terrasa Pons J; Guillem Porta V
Clin Transl Oncol; 2020 Aug; 22(8):1216-1226. PubMed ID: 32002739
[TBL] [Abstract][Full Text] [Related]
16. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment.
Cortesi PA; D'Angiolella LS; Vellucci R; Allegri M; Casale G; Favaretti C; Kheiraoui F; Cesana G; Mantovani LG
PLoS One; 2017; 12(6):e0179523. PubMed ID: 28654672
[TBL] [Abstract][Full Text] [Related]
18. Interference with daily functioning by breakthrough pain in patients with cancer.
Kang JH; Koh SJ; Oh SY; Kim RB; Shin SH; Lee YG; Kim BS; Ryoo HM; Yoon SY; Jang JS; Oh HS; Choi YJ; Lee MH; Lee KH
Support Care Cancer; 2020 Nov; 28(11):5177-5183. PubMed ID: 32056013
[TBL] [Abstract][Full Text] [Related]
19. [Fentanyl buccal tablets in the treatment of breakthrough cancer pain. German cohort of a pan-European multicentre study].
Lux EA; Schwittay A; Kleeberg UR; Papke J
MMW Fortschr Med; 2018 Jul; 160(Suppl 4):18-23. PubMed ID: 29974433
[TBL] [Abstract][Full Text] [Related]
20. High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain.
Amato F; Ceniti S; Mameli S; Pisanu GM; Vellucci R; Palmieri V; Consoletti L; Magaldi D; Notaro P; Marcassa C
Support Care Cancer; 2017 Oct; 25(10):3051-3058. PubMed ID: 28470370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
